Epigenomics AG (ECX):医療機器:M&Aディール及び事業提携情報

【英語タイトル】Epigenomics AG (ECX) - Medical Equipment - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7460)・商品コード:DATA904C7460
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:46
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung, a validating test for the diagnosis of lung cancer. The company’s molecular diagnostic products are based on its proprietary methylation technology, which is based on biological phenomenon called DNA methylation. Epigenomics’ pipeline also comprises tests for monitoring, screening, diagnosis and prognosis assessment of colorectal and lung cancer. It also offers services such as basic research, product development, validate DNA methylation (epigenetic) biomarkers and support for obtaining regulatory approvals. Epigenomics is headquartered in Berlin, Germany.

Epigenomics AG (ECX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Epigenomics AG, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Epigenomics AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Epigenomics AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Epigenomics AG, Medical Equipment, Deal Details 11
Partnerships 11
Biochain Institute Enters into Licensing Agreement with Epigenomics 11
Epigenomics And BioChain Expand Licensing Agreement For Septin9 12
Biochain Institute Enters Into Licensing Agreement With Epigenomics For Septin9 13
Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For Septin9 Biomaker 14
Epigenomics Enters Into Commercialization Agreement With Polymedco For Epi proColon 15
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 16
Equity Offering 17
Epigenomics to Raise Funds Through Rights Offering of Shares 17
Epigenomics Raises USD6.5 Million in Private Placement of Shares 18
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 19
Epigenomics Raises USD5.6 Million in Rights Offering of Shares 20
Epigenomics Raises USD5.3 Million in Private Placement of Shares 21
Epigenomics Completes Private Placement Of Shares For US$4.5 Million 23
Epigenomics Announces Private Placement Of Shares For US$1.3 Million 24
Epigenomics Completes Rights Issue Of Common Stock For US$6 Million 25
Epigenomics Completes Private Placement Of Shares For US$0.7 Million 26
Debt Offering 27
Epigenomics Raises USD8.5 Million in Private Placement of Bonds 27
Epigenomics Announces Private Placement Of Bonds For US$6.7 Million 28
Acquisition 29
Cathay Fortune International to Acquire Epigenomics 29
Epigenomics AG – Key Competitors 31
Epigenomics AG – Key Employees 32
Epigenomics AG – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Aug 08, 2018: Epigenomics Announces 2018 Second Quarter and Six Month Financial Results 34
May 09, 2018: Epigenomics announces 2018 First Quarter Financial Results 35
Mar 23, 2018: Epigenomics Reports Results for Financial Year 2017 36
Nov 15, 2017: Epigenomics Announces 2017 Third Quarter and Nine Months Financial Results 38
Aug 09, 2017: Epigenomics Announces 2017 Second Quarter and Six Months Financial Results 39
Jul 06, 2017: Epigenomics issues change in guidance for financial year 2017 40
May 10, 2017: Epigenomics announces 2017 First Quarter Financial Results 41
Apr 26, 2017: Epigenomics Reports Results for Financial Year 2016 42
Corporate Communications 43
Nov 29, 2017: Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive VP Finance and a Member of the Management Board (Vorstand) 43
Nov 08, 2017: Epigenomics Appointment of Director Reimbursement and Medical Affairs 44
Nov 05, 2017: Supervisory Board of Epigenomics Appoints Dr. Jorge Garces as President and Chief Scientific Officer 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Epigenomics AG, Medical Equipment, Key Facts, 2017 2
Epigenomics AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Epigenomics AG, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Epigenomics AG, Deals By Market, 2012 to YTD 2018 9
Epigenomics AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Biochain Institute Enters into Licensing Agreement with Epigenomics 11
Epigenomics And BioChain Expand Licensing Agreement For Septin9 12
Biochain Institute Enters Into Licensing Agreement With Epigenomics For Septin9 13
Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For Septin9 Biomaker 14
Epigenomics Enters Into Commercialization Agreement With Polymedco For Epi proColon 15
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 16
Epigenomics to Raise Funds Through Rights Offering of Shares 17
Epigenomics Raises USD6.5 Million in Private Placement of Shares 18
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 19
Epigenomics Raises USD5.6 Million in Rights Offering of Shares 20
Epigenomics Raises USD5.3 Million in Private Placement of Shares 21
Epigenomics Completes Private Placement Of Shares For US$4.5 Million 23
Epigenomics Announces Private Placement Of Shares For US$1.3 Million 24
Epigenomics Completes Rights Issue Of Common Stock For US$6 Million 25
Epigenomics Completes Private Placement Of Shares For US$0.7 Million 26
Epigenomics Raises USD8.5 Million in Private Placement of Bonds 27
Epigenomics Announces Private Placement Of Bonds For US$6.7 Million 28
Cathay Fortune International to Acquire Epigenomics 29
Epigenomics AG, Key Competitors 31
Epigenomics AG, Key Employees 32
Epigenomics AG, Subsidiaries 33

List of Figures
Epigenomics AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Epigenomics AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Epigenomics AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Epigenomics AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Epigenomics AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Epigenomics AG, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★調査レポート[Epigenomics AG (ECX):医療機器:M&Aディール及び事業提携情報] (コード:DATA904C7460)販売に関する免責事項を必ずご確認ください。
★調査レポート[Epigenomics AG (ECX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆